TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02202980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily
Study: NCT00775255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin 250 mg/5 mL powder for oral suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin 250 mg/5 mL powder for oral suspension
Study: NCT02202980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet administered orally once daily with food
Study: NCT04729790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRIM-DJ2727
Description: oral FMT capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRIM-DJ2727
Description: oral FMT capsules
Study: NCT03309267

Intervention type: PROCEDURE
Intervention: Serratus anterior plane block
Description: Serratus anterior plane block+patient controlled analgesia
Study: NCT03559270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study: NCT02202980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet administered orally once daily with food
Study: NCT03508635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125134
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125134
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125134
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125134
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125134
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125134
Description: Oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo of CORT125134
Description: Placebo
Study: NCT03559270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study: NCT02096978

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preparing the osteotomy to accept a standard implant device
Description: Preparing the osteotomy with one of two randomly assigned protocols

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preparing the osteotomy to accept a standard implant device
Description: Preparing the osteotomy with one of two randomly assigned protocols
Study: NCT00570843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: New PEG based artificial tear
Description: 1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Optive
Description: 1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
Study: NCT02202980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet administered orally once daily with food
Study: NCT02904759

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01600729

Intervention type: DRUG
Intervention: No Intervention
Description: No intervention.
Study: NCT02006017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence summary alone plus a recommendation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence summary alone plus a recommendation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence summary alone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence summary alone
Study: NCT03876249

Intervention type: OTHER
Intervention: exposure to RSV
Description: No intervention will be given, children naturally exposed to RSV in their early life

Intervention type: OTHER
Intervention: exposure to RSV
Description: No intervention will be given, children naturally exposed to RSV in their early life
Study: NCT02620813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Description: Subjects will apply 0.5% tretinoin cream nightly to their face for a total of 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Subjects will take isotretinoin as prescribed by their dermatologist.
Study: NCT01806116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Study: NCT02615769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: focused information of spirometry in the invitation
Description: Focused information of spirometry in the invitation to the preventive health check compose the intervention in this trial.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard invitation
Description: The active comparator will receive a standard invitation to the preventive health checks. The preventive health checks in the active comparator group and the intervention group are identical.
Study: NCT03508635

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo of CORT125134
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo of CORT125134
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Active comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Challenge agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Challenge agent
Study: NCT02440516

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early treatment group
Description: Physical- and occupational Therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Late treatment group
Description: Waiting list - then Physical- and occupational Therapy
Study: NCT02662088

Intervention type: PROCEDURE
Intervention: laparoscopic-lavage
Study: NCT04349631

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-adMSCs
Description: Five IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory values will be collected prior to first infusion and compared at following visits. Safety labs will be assessed at weeks 6, 14, 26. Inflammatory markers will be assessed at weeks 6, 14, 26. SF-36 and PHQ-9 questionnaires will be assessed at weeks 2, 6, 10, 14, 18, 22, 26.
Study: NCT04671537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preloading with crystalloid fluid
Description: crystalloid fluid at 10 ml/kg of ideal body weight was administered intravenously in 30 min before the BCP for patients
Study: NCT00641784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: Intravenous Magnesium 6 gram load, 3 grams/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedlipine
Description: Oral Nifedpine 10 mgs q 20 min to effect (max 40mgs)...then 20 mgs q 4hrs
Study: NCT00484419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam HCl
Description: coleveselam tablets 625 mg; 6 tablets/day
Study: NCT02979574

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electro-Acupuncture (EA)
Description: Participants will receive 10 treatment of Electro-Acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week). The acupuncturist will insert acupuncture needles in at least 4 local points around the body with the most pain and at least 4 distant points to address the patient's baseline constitution. The needles will be electrically stimulate at 2 Hz by connecting to a TENS unit. The needles will be in place for 30 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electro-Acupuncture (EA)
Description: Participants will receive 10 treatment of Electro-Acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week). The acupuncturist will insert acupuncture needles in at least 4 local points around the body with the most pain and at least 4 distant points to address the patient's baseline constitution. The needles will be electrically stimulate at 2 Hz by connecting to a TENS unit. The needles will be in place for 30 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Battle Field Acupuncture (BFA)
Description: Participants will receive 10 treatment of Battle Field Acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week). Acupuncture needles will be placed in the participants' ears. The total duration of BFA delivery is about 10 to 20 minutes depending on how many needles are used in the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Battle Field Acupuncture (BFA)
Description: Participants will receive 10 treatment of Battle Field Acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week). Acupuncture needles will be placed in the participants' ears. The total duration of BFA delivery is about 10 to 20 minutes depending on how many needles are used in the procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wait List Control (WLC)
Description: After the waiting period (12 weeks from randomization), participants in the WLC will receive up to ten treatments of either EA or BFA based on their personal preference.
Study: NCT00484419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone maleate
Description: rosiglitazone tablets 4mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin phosphate
Description: sitagliptin phosphate tablets 100mg/day
Study: NCT00567437

Intervention type: OTHER
Group type: OTHER
Intervention: NT-pro-BNP levels
Description: pre- and post-exercise NT-pro-BNP levels

Intervention type: OTHER
Group type: OTHER
Intervention: NT-pro-BNP levels
Description: pre- and post-exercise NT-pro-BNP levels
Study: NCT04747704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three Principles Counseling
Description: A 10-week insight-based program offered in prisons in a group setting for 2 hours each week. Approximately 15 - 20 adults or youth in custody participate at a time, led by two trained teachers. The curriculum is designed to teach an understanding of the mind and human experience for the purpose of reducing risk factors, uncovering resiliency and to promote emotional and psychological well-being for adults and youth in the criminal justice system. This is taught through a compilation of sessions that speak to the potential, ability and resilience inherent in every individual. Sessions include a mix of lessons, experiential learning, and group conversations.
Study: NCT03477955

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEEK interspinous spacer
Description: To study the Adjacent Segment Degeneration incidence in the supradjacent segment following short lumbar fusion between PEEK and Silicon Interspinous spacers.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEEK interspinous spacer
Description: To study the Adjacent Segment Degeneration incidence in the supradjacent segment following short lumbar fusion between PEEK and Silicon Interspinous spacers.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEEK interspinous spacer
Description: To study the Adjacent Segment Degeneration incidence in the supradjacent segment following short lumbar fusion between PEEK and Silicon Interspinous spacers.
Study: NCT02712437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROSPECT
Description: PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms, including insomnia, through non-pharmacologic approaches.
Study: NCT00788593

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to EUR-1008 (APT-1008) capsules orally daily for 4 days home treatment and 3 to 5 days hospital treatment in the baseline run-in phase, which will then be randomized to either high dose or low dose of EUR-1008 (APT-1008).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUR-1008 (APT-1008) High Dose
Description: EUR-1008 (APT-1008) total high dose 140,000 lipase USP Lipase units will be given as 7 capsules containing 20,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUR-1008 (APT-1008) Low Dose
Description: EUR-1008 (APT-1008) total low dose 35,000 lipase USP Lipase units will be given as 7 capsules containing 5,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
Study: NCT02480231

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Retropubic Midurethral Sling

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Retropubic Midurethral Sling
Study: NCT01606852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: loading dose (0.5 mcg/kg i.v.), followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Study infusion up to 5 days.
Study: NCT03018093

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-CAR-011
Description: CD19-targeted chimeric antigen receptor T cells
Study: NCT03352752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HTC Vive
Description: Wearing VR helmet before operation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Without HTC Vive
Description: Wearing a blindfold before operation
Study: NCT01534637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nausea and vomiting therapy
Description: Receive aprepitant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Receive aprepitant
Study: NCT01922752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-37440
Description: CEP-37440 will be supplied as 25 mg and 100 mg capsules and will be orally administrated daily.~Patients will be enrolled sequentially in dose escalating cohorts to receive CEP-37440 until a maximum tolerated dose has been defined.
Study: NCT03715322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin Inhalant Product
Description: Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.

Intervention type: DRUG
Group type: OTHER
Intervention: Tobramycin Inhalant Product
Description: Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily) plus chest physiotherapy (5 min, once daily)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily) plus chest physiotherapy (5 min, once daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Natural saline inhalation
Description: Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.

Intervention type: DRUG
Group type: OTHER
Intervention: Natural saline inhalation
Description: Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
Study: NCT02322619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Tablets 400 mg
Description: Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Tablets 400 mg
Description: Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited
Study: NCT03912402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-100
Description: Anti-PD-1 monoclonal antibody, IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (or carboplatin)
Description: IV infusion
Study: NCT04757181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The IBD-AID
Description: Subjects will meet with study personnel for to fill out baseline questionnaires (approximately a 1-hour visit). Subjects will be instructed to make dietary changes based one the IBD-AID guidelines. Dietary instruction will be delivered via individual and group sessions led by trained study personnel. Participants will be expected to learn the skills of dietary change to the IBD-AID and will begin their 8 weeks compliance period followed by endpoint measures. Participants are encouraged to attend 3 cooking classes (1.5 hours duration) in our teaching kitchen.
Study: NCT02516384

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: We will use fecal microbiota transplantation (FMT), with fecal material obtained from OpenBiome or donor directed, to assess safety (as primary outcome) and efficacy (as secondary outcome) in adult (\>18 year old) patients with active ulcerative colitis (UC).
Study: NCT01145924

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS TBNF
Description: Transbronchial needle forceps will be use with the EBUS TBNA scope
Study: NCT02582372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and bupivacaine
Description: 10 micrograms of dexmedetomidine plus 12,5 mgrs of bupivacaine subarachnoideal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl and bupivacaine
Description: 25 micrograms of fentanyl plus 12,5 mgrs of bupivacaine subaracnoideal
Study: NCT00805155

Intervention type: DRUG
Intervention: Mometasone Furoate 0.1% Topical Lotion-Reference Product
Description: Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.

Intervention type: DRUG
Intervention: Mometasone Furoate 0.1% Topical Lotion-Reference Product
Description: Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.

Intervention type: DRUG
Intervention: Mometasone Furoate 0.1% Topical Lotion-Reference Product
Description: Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Study: NCT04070209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (BAY1841788)
Description: Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT will consist of 2-5 fractions of highly targeted radiation therapy delivered every other day. The radiation component will be completed in 4-10 days.